NPHLA Daily
NPHLA Daily
Wednesday, November 18, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 3 trial updates, 3 new studies
NPHLA tracked 6 new official records on this desk today: 3 trial updates, 3 new studies. First: New trial registered: FORTIFY (Fighting Osteoporosis With Risedronate Co-Therapy During Incretin)
Metabolic signal
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Current gastroenterology reports: “Nutrition in the Era of Incretin-Based Therapies: Clinical Strategies for Optimizing Care”.
Regulatory signal
What changed today in Regulatory: 1 proposed rule
NPHLA tracked 1 new official record on this desk today: 1 proposed rule. First: Proposed rule published: Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition.
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 trial update, 1 recall record
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 recall record. First: Trial status changed to “Recruiting”: AWAKENING (Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia)
One thing worth watching
Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…
November 26, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 3 trial updates, 3 new studies
- What changed today in Aesthetics & Longevity: 1 trial update, 1 recall record
- What changed today in Metabolic: 1 new study
- What changed today in Regulatory: 1 proposed rule
- Trial status changed to “Recruiting”: AWAKENING (Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia) (ClinicalTrials.gov (U.S. National Library of Medicine))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.

